RN1201, Refractory Autoimmune Disease Allogeneic Dual-Target CAR-T Phase 1 Trial Recruitment
Clinical Design and Developer
Nanjing Medical University Affiliated Hospital is leading the NCT07105735, a Chinese Phase 1 exploratory trial recruiting 18 patients with autoimmune diseases refractory to standard treatment. The trial is scheduled to start in August 2025 and aims for completion by December 2027. It involves a single intravenous administration of RN1201, a candidate developed by Chongqing Lunning Biotechnology. RN1201 is a development code for an allogeneic chimeric antigen receptor T-cell (CAR-T) therapy targeting both CD19 and B-cell maturation antigen (BCMA), and is still in the pre-commercial branding and generic name assignment stage.
Dual-Target Immune Reset Strategy
CD19 targets a broad range of B cells, while BCMA targets plasma cell lineage responsible for antibody production. The therapy is designed to simultaneously eliminate pathogenic B cells and long-lived plasma cells, aiming to more deeply deplete autoantibody-producing sources compared to CD19-only CAR-T, thereby inducing immune reset. Target diseases include immune thrombocytopenia, autoimmune hemolytic anemia, systemic lupus erythematosus, immune-mediated necrotizing myopathy, neuromyelitis optica spectrum disorder, multiple sclerosis, and myasthenia gravis. While the clinical heterogeneity is high, the platform's broad applicability can be rapidly explored.
Safety Validation as First Value Inflection Point
Patients receive lymphodepletion with fludarabine 30 mg/m² and cyclophosphamide 300 mg/m² over three days, followed by a single dose of RN1201 on Day 0. Primary endpoints are treatment-related adverse events (TEAE) and dose-limiting toxicity (DLT). Key safety variables include cytokine release syndrome (CRS), neurotoxicity (ICANS), graft-versus-host disease (GvHD), and infection. The allogeneic product's immediate availability and batch production advantages can reduce the long manufacturing time of autologous CAR-T, but the balance between donor cell elimination and in vivo persistence will determine clinical value and manufacturing economics.
Competitive Landscape and Market Implications
Direct competitors include Cabaletta Bio (CABA)'s CD19 autologous CAR-T resecabtagene autoleucel (rese-cel, CABA-201) in Phase 1/2, Kyverna Therapeutics (KYTX)'s mivocabtagene autoleucel (miv-cel, KYV-101) in Phase 1/2–2, and Fate Therapeutics (FATE)'s allogeneic CD19 CAR-T FT819 in Phase 1–2. Current standard treatments include corticosteroids, rituximab, immunosuppressants, and disease-specific biologics. In myasthenia gravis, argenx (ARGX)'s efgartigimod (Vibeglen) forms an FcRn inhibition competitive axis. The global autoimmune disease treatment market is estimated at approximately USD 168.6 billion in 2025, but RN1201 has not yet received FDA, EMA, or PMDA approval or advisory committee review, so early safety, pharmacokinetics, and disease-specific response data will serve as benchmarks for subsequent development.
RN1201 is a Phase 1 allogeneic CAR-T trial targeting both CD19 and BCMA. Even with a small cohort of 18 patients, data on GvHD, CRS, ICANS, and cell persistence will serve as the first basis for evaluating platform value. In the short term, it lags behind Cabaletta Bio (CABA)'s rese-cel Phase 1/2 and Kyverna Therapeutics (KYTX)'s miv-cel Phase 1/2–2 in development stage, but donor cell-based immediate supply and repeatable batch production can differentiate its commercial cost structure. In the medium to long term, the potential for single-dose immune reset could challenge the chronic immunosuppressant and FcRn inhibitor administration model in the USD 168.6 billion autoimmune disease treatment market by 2025. However, the inclusion of multiple diseases in a single trial may limit disease-specific efficacy interpretation, making subsequent expanded cohorts and regulatory approval trials key decision points for investment.
Source: ClinicalTrials.gov (api_ct)